FDA Approves Avacopan for the Treatment of ANCA-Associated Vasculitis

On Oct. 8, ChemoCentryx Inc. announced that the U.S. Food & Drug Administration (FDA) has approved avacopan (TAVNEOS), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms... [Read More]

Source: The Rheumatologist - October 8, 2021 Category: Rheumatology Authors: ChemoCentryx Tags: Biologics & Biosimilars Conditions Drug Updates Vasculitis avacopan Source Type: research